TITLE

VICAL LICENCEE ANGES MG FILES NDA IN JAPAN FOR COLLATEGENE

PUB. DATE
May 2008
SOURCE
Worldwide Biotech;May2008, Vol. 20 Issue 5, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare by AnGes MG Inc. for its angiogenesis product candidate, Collategene. The product is for treatment of critical limb ischemia, which uses Vical Inc. technology to deliver a gene encoding hepatocyte growth factor (HGF). HGF is a human protein that causes growth of blood vessels in areas of restricted blood flow.
ACCESSION #
31784380

 

Related Articles

  • CRITICAL LIMB IS CHEMIA : ADVANCED MEDICAL THERAPY. Davies, Mark G. // Methodist DeBakey Cardiovascular Journal;Oct-Dec2012, Vol. 8 Issue 4, p3 

    Systemic atherosclerosis and its risk factors are present in the majority of patients with critical limb ischemia. Aggressive medical therapy is an immediate and necessary part of the work-up and management of these patients and will involve a multidisciplinary approach. Risk stratification...

  • FDA, Vical Licensee Agree on Phase III Design for Collategene. Hollingsworth, Catherine // BioWorld Today;1/13/2010, Vol. 21 Issue 8, p4 

    The article reports on an agreement reached by AnGes MG Inc. with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase III trial of Collategene. It is noted that Collategene has the potential to treat patients with peripheral arterial disease (PAD). The underlying...

  • Vical Prices $33.8M Offering on Heels of Partner Setbacks. Morrison, Trista // BioWorld Today;9/27/2010, Vol. 21 Issue 186, p1 

    The article reports on the plan of Vical Inc. to raise 33.8 million U.S. dollars through a public offering following the announcement of setbacks by its partners. Sanofi-Aventis Group SA has confirmed the failure of a Phase III trial for the drug Temusi, while AnGes MG Inc. decided to abandon a...

  • Management of Fasciotomy Wounds-Does the Dressing Matter? MATT, SARAH E.; JOHNSON, LAURA S.; SHUPP, JEFFREY W.; KHEIRBEK, TAREQ; SAVA, JACK A. // American Surgeon;Dec2011, Vol. 77 Issue 12, p1656 

    Fasciotomy is a limb-saving procedure in the management of ischemic extremities. Little evidence exists as to the best method of fasciotomy wound management. We hypothesized that the use of vacuum dressing (VAC) or creation of dynamic tension (DYN) would increase rates of primary closure,...

  • HGF/SF Activates Glycolysis and Oxidative Phosphorylation in DA3 Murine Mammary Cancer Cells. Kaplan, Ofer; Firon, Michal; Vivi, Antonio; Navon, Gil; Tsarfaty, Ilan // Neoplasia;Jul2000, Vol. 2 Issue 4, p365 

    Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine growth factor which increases cellular motility and has also been implicated in tumor development and progression and in angiogenesis. Little is known about the metabolic alteration induced in cells following Met-HGF/SF signal...

  • ERRATUM.  // Current Signal Transduction Therapy;Sep2011, Vol. 6 Issue 3, p441 

    A correction to the article "Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases" is presented.

  • Scatter factor/hepatocyte growth factor is essential for liver development. Schmidt, Claudia; Bladt, Friedhelm // Nature;2/23/1995, Vol. 373 Issue 6516, p699 

    Reports that scater factor/hepatocyte growth factor is essential for liver development. Reduction of liver size; Loss of parenchymal cells; Impairment of placental trophoblast cells.

  • Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Uehara, Yoshihiko; Minowa, Osamu // Nature;2/23/1995, Vol. 373 Issue 6516, p702 

    Reports on the occurrence of placental defect and embryonic lethality in mice lacking hepatocyte growth factor. Functions of hepatocyte growth factor.

  • Editorial. Martin, Tracey A.; Jiang, Wen G. // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 1, p1 

    The article discusses various reports published within the issue including one about the main characteristics of the hepatocyte growth factor (HGF) in cancer and another on the clinical implications for the HGF antagonist.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics